CytomX Therapeutics announces pricing of public offering of common stock
CytomX Therapeutics announced pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share, for gross proceeds of $125 million. CytomX granted underwriters a 30-day option to purchase up to an additional 765,306 shares. July 12, 2018